By Nick Paul Taylor
A “very important” part of Merck’s HIV strategy has come off the rails. Just months after talking up the importance of MK-8507, Merck has paused development of the asset in response to midphase data that also raised questions about the backbone of all the company’s planned HIV regimens.
read more
By Robert King
The House passed a massive roughly $2 trillion infrastructure bill that includes drug price reforms, closes the Medicaid coverage gap and cuts DSH payments to hospitals in states that did not expand Medicaid.
read more
By Fraiser Kansteiner
The pharma industry should emerge mostly unscathed if President Joseph Biden's Build Back Better bill makes its way into law. While the legislation would open the door to limited Medicare negotiations and cap price hikes at the rate of inflation, the cost to the industry and its pace of innovation would be minimal, a government analysis found.
read more
By Dave Muoio
The American Medical Association, the American College of Physicians and dozens of other healthcare organizations and individual health experts called on employers to voluntarily implement OSHA's "reasonable and essential" vaccination requirements.
read more
By Conor Hale
With a total footprint of about 4 feet by 3 feet, the cobas 5800 comes in a smaller package compared to the company’s high-throughput heavyweights in the cobas 6800 and 8800.
read more
By Fraiser Kansteiner
Hungry for details on Pfizer's COVID-19 vaccine? Just file a FOIA request and wait until the U.S. Tricentennial in 2076. That's the schedule the FDA proposed in documents filed in a U.S. District Court this week.
read more
By Annalee Armstrong
Just days ago, Bristol Myers was touting new data for the targeted heart drug mavacamten. Now, the Big Pharma has announced that the FDA has extended the decision date for the drug, which was nabbed through the $13 billion buyout of MyoKardia.
read more
By Ben Adams
Enanta Pharmaceuticals is shutting down work on its oral hepatitis B program for EDP-721 after serious safety red flags were raised in a phase 1 study.
read more
By Eric Sagonowsky
BioMarin has won the FDA's go-ahead for its next big launch. But the drug's arrival may be unwelcome news for those who've built a community out of living full lives with dwarfism.
read more
By Rebecca Torrence
Trusted Health has raised $149 million to develop its staffing platform which matches nurses with open positions. The startup's AI-powered platform has already been deployed at more than 40 Mercy hospitals.
read more
By Conor Hale
After picking up $200 million just over six months ago, Benchling isn’t sitting still. The cloud-based R&D platform developer collected another $100 million to help power its global expansion plans.
read more
By Arlene Weintraub
A Brigham and Women's and MIT team discovered that T cells and cancer cells connect to each other with tiny tendrils, and that the cancer cells use those connections to suck energy from T cells. Inhibiting the formation of the tendrils could enhance immuno-oncology treatments, they suggested.
read more
